US Stock MarketDetailed Quotes
SLNO Soleno Therapeutics
- 44.9900
- -2.6500-5.56%
Close May 10 16:00 ET
1.66BMarket Cap-21734P/E (TTM)
47.9200High42.6000Low546.06KVolume47.6400Open47.6400Pre Close24.41MTurnover3.13%Turnover RatioLossP/E (Static)36.86MShares53.820052wk High11.42P/B784.48MFloat Cap3.690052wk Low--Dividend TTM17.44MShs Float742.5000Historical High--Div YieldTTM11.17%Amplitude0.8500Historical Low44.7060Avg Price1Lot Size
About Soleno Therapeutics Company
Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.
Company Profile
SymbolSLNO
Company NameSoleno Therapeutics
Listing DateNov 13, 2014
Founded1999
CEODr. Anish Bhatnagar, M.D.
MarketNASDAQ
Employees42
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address203 Redwood Shores Parkway,Suite 500
CityRedwood City
ProvinceCalifornia
CountryUnited States of America
Zip Code94065
Phone1-650-213-8444
Websitehttp://www.soleno.life
Company Executives
- Name
- Position
- Salary
- Dr. Anish Bhatnagar, M.D.
- President, Chief Executive Officer, Chief Operating Officer and Director
- 4.12M
- Meredith S. Manning
- Chief Commercial Officer
- --
- James H. Mackaness
- Chief Financial Officer and Principal Accounting Officer
- 1.21M
- Patricia C. Hirano
- Senior Vice President, Regulatory Affairs
- 1.03M
- Kristen Yen
- Senior Vice President, Clinical Operations
- --
- Dr. Michael Huang, M.D.
- Senior Vice President, Clinical Development
- --
- Dr. Ernest Mario,PhD
- Chairman of the Board
- 131.87K
- Dr. Andrew Sinclair, PhD
- Independent Director
- 51.87K
- Dr. Birgitte Volck, M.D.,PhD
- Independent Director
- 102.87K
- Matthew Pauls
- Independent Director
- 70.53K
- Gwen A. Melincoff
- Independent Director
- 100.37K
- William G. Harris
- Independent Director
- 111.87K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg